Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Alaunos Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -68.24%.
The industry rank for Alaunos Therapeutics's 3-Year RORE % or its related term are showing as below:
TCRT's 3-Year RORE % is ranked worse than 87.98% of 1289
companies
in the Biotechnology industry
Industry Median: -11.53
vs TCRT: -68.24
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Alaunos Therapeutics 3-Year RORE % Related Terms
Alaunos Therapeutics 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Alaunos Therapeutics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCRT vs DRMA, MBIO, ELAB: 3-Year RORE % Comparison
For the Biotechnology subindustry, Alaunos Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alaunos Therapeutics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Alaunos Therapeutics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Alaunos Therapeutics (TCRT) has a 3-Year RORE % of -68.24 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Alaunos Therapeutics and its competitors. According to the industry distribution chart, Alaunos Therapeutics ranks #1134 out of 1289 companies in the Biotechnology industry, placing it in the top 88%.
Is Alaunos Therapeutics' 3-Year RORE % too high?
Alaunos Therapeutics' current 3-Year RORE % is -68.24. Based on the distribution chart, Alaunos Therapeutics ranks #1134 out of 1289 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' 3-Year RORE % compare to DRMA and MBIO?
According to the Biotechnology industry distribution chart, Alaunos Therapeutics ranks #1134 out of 1289 companies for 3-Year RORE %. This places Alaunos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current 3-Year RORE % is -68.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.12 — trading 211.8% above its estimated fair value. The current 3-Year RORE % is -68.24. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current 3-Year RORE % is -68.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alaunos Therapeutics (TCRT) Overvalued in 2026?
Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued.
The current stock price of $2.12 is trading 211.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.
Key valuation signals for TCRT:
3-Year RORE %: -68.24
GF Value™: $0.68 vs. price of $2.12 (211.8% above fair value)
No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score
Get the complete analysis for TCRT
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRT has been successfully added to your 
